{
    "clinical_study": {
        "@rank": "28515", 
        "acronym": "ABRAZO", 
        "arm_group": {
            "arm_group_label": "BMN 673", 
            "arm_group_type": "Experimental", 
            "description": "Cohort 1) Subjects who have previously responded to a platinum-containing regimen for metastatic disease with disease progression > 8 weeks following the last dose of platinum\nCohort 2) Subjects who have received > 2 prior chemotherapy regimens and who have had no prior platinum therapy for metastatic disease"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this 2-stage, 2-cohort Phase 2 trial is to evaluate the safety and efficacy\n      of BMN 673 in subjects with locally advanced or metastatic breast cancer with a deleterious\n      germline BRCA 1 or BRCA 2 mutation.  Subjects will be assigned to either Cohort 1 or 2 based\n      on prior chemotherapy for metastatic disease:\n\n        -  Cohort 1) Subjects who have previously responded to platinum-containing regimen for\n           metastatic disease with disease progression > 8 weeks following the last dose of\n           platinum; or\n\n        -  Cohort 2) Subjects who have received > 2 chemotherapy regimens and who have had no\n           prior platinum therapy for metastatic disease"
        }, 
        "brief_title": "A Phase 2, 2-Stage, 2-Cohort Study of BMN 673 in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)", 
        "condition": [
            "Breast Neoplasms", 
            "BRCA 1 Gene Mutation", 
            "BRCA 2 Gene Mutation"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed carcinoma of the breast\n\n          -  Locally advanced and/or metastatic disease\n\n          -  Deleterious or pathogenic germline BRCA 1 or BRCA 2 mutation\n\n          -  Prior chemotherapy: Cohort 1) PR or CR to prior platinum-containing regimen for\n             metastatic disease with disease progression > 8 weeks following the last dose of\n             platinum; or Cohort 2) > 2 prior chemotherapy regimens for metastatic disease and no\n             prior platinum for metastatic disease\n\n          -  ECOG performance status \u2264 1\n\n          -  Have adequate organ function\n\n        Exclusion Criteria:\n\n          -  Prior enrollment into a clinical trial of a PARP inhibitor\n\n          -  CNS metastasis except adequately treated brain metastasis documented by baseline CT\n             or MRI scan that has not progressed since previous scans and that does not require\n             corticosteroids for management of CNS symptoms\n\n          -  Prior malignancy except for prior BRCA-associated cancer as long as there is no\n             current evidence of the prior cancer, carcinoma in situ of the cervix or non-melanoma\n             skin cancer, and a cancer diagnosed and definitively treated >5 years prior to study\n             enrollment with no subsequent evidence of recurrence\n\n          -  Known to be HIV positive, active hepatitis C virus, or active hepatitis B virus\n\n          -  Known hypersensitivity to any of the components of BMN 673"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02034916", 
            "org_study_id": "673-201"
        }, 
        "intervention": {
            "arm_group_label": "BMN 673", 
            "intervention_name": "BMN 673", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Breast cancer", 
            "BRCA mutation", 
            "PARP inhibitor", 
            "BRCA 1", 
            "BRCA 2"
        ], 
        "lastchanged_date": "May 20, 2014", 
        "location": [
            {
                "contact": {
                    "email": "jchang@marinspecialtycare.com", 
                    "last_name": "Jaime Chang, BS,CCRP", 
                    "phone": "415-925-5040"
                }, 
                "facility": {
                    "address": {
                        "city": "Greenbrae", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94904"
                    }, 
                    "name": "Marin Cancer Care, Inc."
                }, 
                "investigator": {
                    "last_name": "Peter D. Eisenberg, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "soverbey@utmck.edu", 
                    "last_name": "Shanna Overbey, B, RN", 
                    "phone": "865-305-9773"
                }, 
                "facility": {
                    "address": {
                        "city": "Knoxville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37920"
                    }, 
                    "name": "University of Tennessee Medical Center"
                }, 
                "investigator": {
                    "last_name": "Timothy J. Panella, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2, 2-Stage, 2-Cohort Study of BMN 673 Administered to Germline BRCA Mutation Subjects With Locally Advanced and/or Metastatic Breast Cancer", 
        "other_outcome": {
            "measure": "Health-related quality of life", 
            "safety_issue": "No", 
            "time_frame": "Anticipated in about 24-30 months following first patient enrolled"
        }, 
        "overall_contact": {
            "email": "dlounsbury@bmrn.com", 
            "last_name": "Debra Lounsbury, RN, MS"
        }, 
        "overall_contact_backup": {
            "email": "dmir@bmrn.com", 
            "last_name": "Denis Mir, MSc"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Determine Objective Response Rate (ORR) for each cohort", 
            "safety_issue": "No", 
            "time_frame": "Anticipated in about 24-30 months following first patient enrolled"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02034916"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Clinical benefit response (CBR) rate defined as CR + PR + SD lasting  \u2265 24 weeks", 
                "safety_issue": "No", 
                "time_frame": "Anticipated in about 24-30 months following first patient enrolled"
            }, 
            {
                "measure": "Duration of response (DOR) for objective responders", 
                "safety_issue": "No", 
                "time_frame": "Anticipated in about 24-30 months following first patient enrolled"
            }, 
            {
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Anticipated in about 24-30 months following first patient enrolled"
            }, 
            {
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Anticipated in about 24-30 months following first patient enrolled"
            }
        ], 
        "source": "BioMarin Pharmaceutical", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Translational Research in Oncology", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Myriad Genetics, Inc.", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "BioMarin Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}